Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN LYSINE versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN LYSINE versus LODINE.
IBUPROFEN LYSINE vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen lysine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
200-800 mg orally every 6-8 hours as needed; maximum 2400 mg/day. Intravenous: 400-800 mg every 6 hours; maximum 3.2 g/day.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
2–4 hours in adults; extended to 4–6 hours in neonates. In severe hepatic or renal impairment, half-life may increase up to 8–10 hours.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Renal excretion of metabolites and conjugates accounts for >90% of elimination; less than 1% is excreted unchanged in urine. Fecal excretion is minimal (<5%).
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category D/X
Category C
NSAID
NSAID